The articles in this supplement were commissioned based on participation in evaluating the Centers for Disease Control and Prevention-funded Colorectal Cancer Screening Demonstration Program.
Clinical outcomes from the CDC's Colorectal Cancer Screening Demonstration Program
Article first published online: 18 JUL 2013
© 2013 American Cancer Society
Special Issue: Comprehensive Evaluation of the Centers for Disease Control and Prevention's Colorectal Cancer Screening Demonstration Program, Supplement to Cancer
Volume 119, Issue Supplement S15, pages 2820–2833, 1 August 2013
How to Cite
Seeff, L. C., Royalty, J., Helsel, W. E., Kammerer, W. G., Boehm, J. E., Dwyer, D. M., Howe, W. R., Joseph, D., Lane, D. S., Laughlin, M., Leypoldt, M., Marroulis, S. C., Mattingly, C. A., Nadel, M. R., Phillips-Angeles, E., Rockwell, T. J., Ryerson, A. B. and Tangka, F. K. L. (2013), Clinical outcomes from the CDC's Colorectal Cancer Screening Demonstration Program. Cancer, 119: 2820–2833. doi: 10.1002/cncr.28163
The opinions or views expressed in this supplement are those of the authors and do not necessarily reflect the opinions or recommendations of the journal editors, the American Cancer Society, John Wiley & Sons, Inc., or the Centers for Disease Control and Prevention.
- Issue published online: 18 JUL 2013
- Article first published online: 18 JUL 2013
- Manuscript Accepted: 6 NOV 2012
- Manuscript Revised: 5 OCT 2012
- Manuscript Received: 11 JUL 2012
- colorectal cancer screening;
- fecal occult blood testing;
- cancer screening programs;
- colorectal cancer prevention
Colorectal cancer remains the second leading cause of cancer-related deaths among US men and women. Screening rates have been slow to increase, and disparities in screening remain.
To address the disparity in screening for this high burden but largely preventable disease, the Centers for Disease Control and Prevention (CDC) designed and established a 4-year Colorectal Cancer Screening Demonstration Program (CRCSDP) in 2005 for low-income, under-insured or uninsured men and women aged 50 to 64 years in 5 participating US program sites. In this report, the authors describe the design of the CRCSDP and the overall clinical findings and screening test performance characteristics, including the positive fecal occult blood testing (FOBT) rate; the rates of polyp, adenoma, and cancer detection with FOBTs and colonoscopies; and the positive predicative value for polyps, adenomas, and cancers.
In total, 5233 individuals at average risk and increased risk were screened for colorectal cancer across all 5 sites, including 44% who underwent screening FOBT and 56% who underwent screening colonoscopy. Overall, 77% of all individuals screened were women. The FOBT positivity rate was 10%. Results from all screening or diagnostic colonoscopies indicated that 75% had negative results and required a repeat screening colonoscopy in 10 years, 16% had low-risk adenomas and required surveillance colonoscopy in 5 to 10 years, 8% had high-risk adenomas and required surveillance colonoscopy in 3 years, and 0.6% had invasive cancers.
This report documents the successes and challenges in implementing the CDC's CRCSDP and describes the clinical outcomes of this 4-year initiative, the patterns in program uptake and test choice, and the comparative test performance characteristics of FOBT versus colonoscopy. Patterns in final outcomes from the follow-up of positive screening tests were consistent with national registry data. Cancer 2013;119(15 suppl):2820–33. © 2013 American Cancer Society.